The 2026 INTERPHEX Exhibitor Awards recognize innovative technologies that advance pharmaceutical and biopharmaceutical manufacturing, from cell culture media preparation and sterile connections to contamination control, filtration, single-use assemblies, and cryogenic containment. The awards are chosen by the editors of American Pharmaceutical Review, Cell and Gene Therapy Review, Pharmaceutical Outsourcing, and Tablets and Capsules magazine and presented at the INTERPHEX show.
Best In Show – Nucleus Biologics, Krakatoa® K500
Nucleus Biologics’ Krakatoa® K500, described as a “Nespresso® for bioproduction solutions,” receives the Best In Show award for transforming how biopharmaceutical manufacturers produce cell culture media and process buffers. The Krakatoa K500 is the first pod-based, bioreactor-scale cell culture media and buffer manufacturing system, capable of producing up to 500 L of GMP-grade solutions on demand in under three hours while reducing costs, accelerating timelines, and simplifying supply chains.
Launched on February 10, 2026, the system addresses a persistent bottleneck in biologics manufacturing: dependence on centralized production and complex supply chains for liquid media and buffers. Instead of relying on bulk liquid shipments or manual powder handling, the Krakatoa K500 allows users to generate media and buffers directly at the point of use using single-use, pre-packed pods. Each pod contains a pre-formulated powdered media or buffer; once the pod is loaded and single-use tubing is connected, the instrument scans an integrated QR code and automates powder hydration, mixing, sterile filtration, and final dispensing in a closed environment.
The platform is designed for GMP compliance and easy facility integration, with a compact footprint, intuitive interface, inline QC sensors for pH, conductivity, and turbidity, and automated digital batch record generation. Economically, it targets one of the largest cost drivers in advanced therapy manufacturing—media and buffers, which can represent 30–40% of COGS—by reducing acquisition costs by up to 50% through on-demand powder-based production, elimination of cold chain, and reduced facility and labor requirements. By moving media and buffer production closer to the point of use, the Krakatoa K500 improves resilience, shortens lead times, and supports broader patient access to advanced therapies.
Best New Product/Service – Ensorcell, Versaweld Sterile Tube Welder
The Versaweld sterile tube welder from Ensorcell is honored as Best New Product/Service for delivering a compact, battery-operated, and highly versatile approach to sterile tube welding in life science environments. Weighing about 9 pounds and measuring roughly 12 inches long, this shoebox-sized device is designed for portability, allowing operators to perform welds wherever they are needed rather than being constrained by bulky, fixed systems.
Versaweld addresses key limitations of conventional tube welders, which are often heavy, tethered to power, reliant on costly sharps-based consumables, and restricted by adapters when switching tube sizes or materials. The platform performs rapid (approximately 30-second) sterile welds—dry-to-dry, dry-to-wet, and wet-to-wet—without disposable blades. Instead, it uses a specialized stainless steel ribbon housed in a patent-pending cassette that supports up to 120 continuous welds. The auto-feeding ribbon reduces sharp waste and eliminates the risks associated with handling and disposing of blades, while integrated clamps keep fluids isolated from the external environment during welding.
A powerful battery enables cable-free operation for an entire cassette’s worth of welds on a single charge, supporting flexible use across a shift. Versaweld’s patent-pending tube selector wheel is a key innovation, allowing users to weld six tube diameters and four materials without changing adapters, with settings that can be saved for quick recall. A tube gauge accessory helps users identify tube inner and outer diameters, streamlining setup. The system is engineered for affordability, offering welds at about half the cost per connection of many alternatives and at a fraction of the cost of some sterile connectors. By combining portability, flexibility, safety, and cost efficiency, Versaweld advances sterile tube welding for modern bioprocessing.
Editor’s Choice – UV Medico, Far-UVC UV222 Dual Downlight
UV Medico’s Far-UVC UV222 Dual Downlight 60x60 earns the Editor’s Choice award for integrating continuous microbial reduction into a standard cleanroom lighting form factor. Launched in 2025, the fixture brings together high-efficiency LED illumination and filtered Far-UVC technology at 222 nm, transforming a ceiling light into an active contamination-control system that can safely operate in occupied environments.
The product addresses the persistent challenge of microbial control in cleanrooms, where human activity remains a major contamination source despite strict gowning, HEPA filtration, and cleaning protocols. Traditional disinfection approaches rely on chemicals that demand long contact times, manual application, and subsequent residue removal, while conventional 254 nm UV systems cannot be used in occupied spaces due to safety concerns. The UV222 Dual Downlight uses filtered Far-UVC light from krypton-chloride excimer lamps at 222 nm, a wavelength shown to inactivate bacteria, viruses, and spores while being absorbed in the outer non-living layer of skin and the tear layer of the eye, allowing operation within accepted exposure limits.
Integrated into a 60 × 60 cm cleanroom luminaire, the fixture maintains required lighting levels and cleanroom integrity while continuously irradiating air and exposed surfaces. Its flush-mounted design preserves laminar airflow and sealing, facilitating replacement of existing fixtures without structural modifications. Reported installations in pharmaceutical pilot facilities demonstrate reductions in airborne microbial counts exceeding 93% in Grade B and C environments and lower surface bioburden on frequently touched areas, supporting improved batch release and fewer contamination excursions. The system accelerates decontamination compared with chemical methods, requires no contact time or residues, and reduces chemical and consumable use. Mercury-free excimer technology supports sustainability, while continuous Far-UVC operation aligns with modern expectations for proactive contamination control in sterile manufacturing.
Best Tech Innovation – Alphinity, TFFi with PIXER Pump
Alphinity’s TFFi platform with PIXER Pump is recognized with the Best Tech Innovation award for reengineering tangential flow filtration around the needs of shear-sensitive biologics, including viral vectors, cell therapies, and vaccines. TFFi is a precision, single-use TFF platform built around the PIXER positive displacement diaphragm pump, and it is the first TFF system designed from the ground up for fragile biologics. Launching commercially at INTERPHEX 2026, the system combines walk-away ISA‑88 recipe automation, error-proof hardware, a 30 mL minimum working volume, and a unified architecture that spans process development through Phase 1–3 clinical manufacturing.
The PIXER pump removes the mechanism of damage inherent in standard peristaltic pumps, which squeeze fluid through tubing with rollers, creating pinch points, tubing fatigue, and spallation. Instead, PIXER uses a flexing diaphragm, eliminating roller–tubing interfaces and significantly reducing shear. In a third-party MilliporeSigma study, PIXER outperformed an established low-shear benchmark pump, delivering 4.4 times better product filterability (Vmax ~350 LMH vs ~80 LMH) even at 16 times the linear velocity, highlighting that pump mechanism—not velocity—is the primary driver of product damage. PIXER also offers ±0.1 PSI pressure stability across its operating range, about 30 times tighter than the nearest competitor’s published specification, enhancing flux consistency, limiting membrane fouling, and improving run-to-run reproducibility.
TFFi combines this pump with ConSynSys automation implementing ISA‑88 batch recipe execution, enabling fully automated UF/DF workflows from equilibration through collection with automated valve sequencing and unattended operation. A minimum working volume of 30 mL, enabled by a system hold-up of 24.8 mL, allows precious early-stage samples to be processed effectively. The same platform covers 30 mL to 10 L, avoiding the need for multiple systems and re-optimization as programs scale. Error-proof, single-use flowpaths based on poka-yoke principles, modular pre-assembled sub-kits, and color-coding minimize the risk of incorrect installation. Dual compatibility with flat-sheet cassettes and hollow-fiber membranes within the same platform further reduces capital and footprint. By directly addressing pump-induced damage—an underappreciated source of yield loss—TFFi brings together low shear, benchtop-scale automation, small working volumes, and a straight path from process development to GMP manufacturing.
INTERPHEX Efficiency Champion – Eldon James Corp, BioKlik™ Assemblies
Eldon James Corp’s BioKlik™ assemblies receive the INTERPHEX Efficiency Champion award for redefining how single-use tubing assemblies are built and deployed in biopharmaceutical production. BioKlik is a ready-to-use tubing solution that converts what is normally a complex, time-intensive build into a process that takes minutes. Using patented “connection innovation” technology, BioKlik components feature ultra low-profile, ergonomic, leak-free quick-connect couplings that can be assembled or reconfigured quickly without compromising sterility.
The modular architecture allows facilities to mix and match components to build tube runs, manifolds, and sampling ports tailored to specific process geometries, facilitating rapid scale-up, equipment swaps, and process upgrades with less downtime, reduced waste, and simplified lab design. Off-the-shelf assemblies provide quick, reliable options with the same focus on quality as custom solutions, enabling faster deployment when timelines are tight.
At the heart of the platform is the integrated SeriesLock® Xgen® multi-connect coupler, designed to make up to ten reconnections without compromising sterile integrity, as demonstrated in bacterial ingress studies. By enabling repeated connections, SeriesLock Xgen reduces dependence on disposable connectors and supports a more circular, sustainability-oriented approach in cleanrooms. The SeriesLock® spring-free flow path® sterile quick-disconnect coupler further increases flow capacity, allows disconnection while maintaining a sterile flow path, and permits one subsequent reconnection.
BioKlik assemblies are positioned as the “LEGO blocks” of biopharma fluid management: modular, customizable, and easy to assemble. Key benefits include innovation in connection technology, flexibility and scalability across processes, reduced risk of errors, shorter configuration and troubleshooting time, and improved cost efficiency. By enabling rapid configuration changes in process development and ensuring consistent performance in manufacturing, BioKlik assemblies help safeguard product integrity, trim operational expense, and support a greener, more resilient biomanufacturing ecosystem.
Biotech Innovation Award – BioLife, CellSeal® CryoCase
BioLife’s CellSeal® CryoCase receives the Biotech Innovation Award for introducing a rigid, cryogenic-compatible containment system designed to protect frozen cell and gene therapy drug products across cryopreservation, storage, transport, and thaw. Introduced in May 2025, CryoCase was created to address structural vulnerabilities associated with flexible cryobags, which can suffer from stress fractures, seal stress, and accidental damage at ultra-low temperatures, particularly as manufacturing scales and global distribution grows.
Container failure at the frozen drug product stage can lead to therapy loss, delays, increased scrutiny, and higher costs—and for autologous therapies, such failures directly affect individual patients. CryoCase mitigates these risks by surrounding the frozen drug product with rigid external protection engineered specifically for cryogenic environments. Rather than representing an incremental improvement to bag materials, the system offers a structural redesign of containment.
By reducing mechanical stress throughout controlled-rate freezing, long-term storage, distribution, and thaw, CryoCase improves durability and handling reliability while remaining compatible with closed-system processing. The design supports reduced risk of container breakage, improved inspection visibility for sterility and quality review, and true closed-system automation. As regulators and manufacturers place greater emphasis on container integrity, manufacturing controls, and handling reliability, CellSeal CryoCase reframes cryopreservation as an engineered risk-mitigation step. By embedding structural protection and inspection capability into the frozen drug product configuration, it strengthens one of the most fragile stages of cell therapy manufacturing and helps ensure that advanced therapies reach patients safely and consistently.
All 2026 INTERPHEX Exhibitor Awards will be presented to the winners during the first day of the INTERPHEX show, recognizing their contributions to more efficient, reliable, and innovative pharmaceutical and biopharmaceutical manufacturing.